ArticleIn vivo (Athens, Greece)
Older Age and Outcomes of Intravesical Bacillus Calmette-Guérin for Non-muscle-invasive Bladder Cancer.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimIntravesical bacillus Calmette-Guérin (BCG) therapy is the standard adjuvant treatment for high-risk non-muscle-invasive bladder cancer (NMIBC). However, the impact of advanced age, particularly ≥80 years, on oncological outcomes of BCG therapy remains controversial. This study evaluated age-stratified outcomes and real-world BCG delivery in patients with NMIBC. PATIENTS AND
methodsWe retrospectively reviewed 120 consecutive patients with NMIBC who initiated intravesical BCG therapy between June 2019 and May 2025 at a single center. Patients were stratified by age at BCG initiation into <80 years (n=91) and ≥80 years (n=29). High-risk recurrence-free survival (HR-RFS), progression-free survival (PFS), metastasis-free survival (MFS), and overall survival (OS) were assessed. HR-RFS was defined as the time from BCG initiation to recurrence of high-risk NMIBC or disease progression. Survival outcomes were estimated using the Kaplan-Meier method and compared between groups.
resultsBaseline clinicopathological characteristics and the rate of achieving the institution-defined minimum BCG exposure were similar between the two age groups. During a median follow-up of 33.5 months, there were no significant differences in HR-RFS (
conclusionIn this real-world cohort, intravesical BCG therapy achieved comparable oncological outcomes in patients aged ≥80 years and younger patients with NMIBC. Chronological age alone was not associated with inferior clinically meaningful disease control, supporting BCG use in older patients when clinically indicated, with treatment decisions guided by tolerability and patient preference.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.